Schonfeld Strategic Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-11,100	Closed	-$463K	–	2394
2021 Q1	$463K	Buy	11,100 +388	+4%	+$18K	0.01%	1175
2020 Q4	$500K	Buy	+10,712	New	+$501K	0.01%	1042
2018 Q2	–	Sell	-8,104	Closed	-$427K	–	1015
2018 Q1	$427K	Buy	+8,104	New	+$471K	0.03%	512
2016 Q3	–	Sell	-13,135	Closed	-$510K	–	576
2016 Q2	$510K	Buy	+13,135	New	+$547K	0.11%	221

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Schonfeld Strategic Advisors's EGRX Position: Q2 2021 in Review

Schonfeld Strategic Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2021, closing a stake of 11,100 shares — an estimated $463K sold.

Schonfeld Strategic Advisors first reported a position in EGRX in Q2 2016 and held it in 4 quarters. The position peaked at $510K in Q2 2016. 146 funds tracked by Wall St. Rank hold EGRX as of Q2 2021.

Schonfeld Strategic Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Schonfeld Strategic Advisors sold 11,100 Eagle Pharmaceuticals, Inc. shares in Q2 2021, an estimated $463K.
Schonfeld Strategic Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2016 and held it in 4 quarters.
Schonfeld Strategic Advisors's Eagle Pharmaceuticals, Inc. position peaked at $510K in Q2 2016.
146 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.